Stock Monitor: Highwoods Properties Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd. (NASDAQ: ARCT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=ARCT as the Company's latest news hit the wire. On February 12, 2018, the leading RNA medicines Company declared that it has appointed Dr. Christine Esau as the Vice President of Research and Development (R&D), effective immediately. Dr. Christine Esau was previously serving as the Senior Director of Translational Research in the Company. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Highwoods Properties, Inc. (NYSE: HIW), which also belongs to the Financial sector as the Company Arcturus Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Arcturus Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
New Appointments Follow CEO's Termination
This announcement comes days after Arcturus terminated its President and Chief Executive Officer Joseph E. Payne on February 02, 2018, for conduct that its Board of Directors deemed to be contrary to the best interests of the Company and its shareholders. Concurrently, the Company also appointed Mark R. Herbert as the Interim President, effective immediately. Mark was previously serving as the Vice President of Business Development and Alliance Management at Arcturus.
Overview of Christine Esau's Work Profile
Before joining Arcturus in 2015, Christine Esau was serving as the lead biologist at Ionis Pharmaceuticals and Regulus Therapeutics. She also worked as the Chief Scientific Officer of AptamiR Therapeutics. At Arcturus, Dr. Esau was recently serving as the Senior Director of Translational Research.
Christine Esau's role in Regulus Therapeutics - Christine Esau has done some pioneering work in microRNA biology and anti-miRNA targeting technology development during her career at Regulus. Her work has also featured in several landmark, highly cited papers, and early patent filings. Dr. Esau moved the anti-miR-122 program from discovery biology to lead compound selection during her role as the lead biologist for the program. Simultaneously, she directed pharmacology, PK/PD, safety, and mechanism of action studies.
At Regulus, she also led experiments to identify innovative microRNA targets for metabolic diseases, and in that process, she established an extensive network of academic collaborators. Dr. Esau also headed the anti-miR-33 program for atherosclerosis, which subsequently, became the basis for Regulus' partnership with Astra-Zeneca.
Christine Esau's role in AptamiR Therapeutics - At AptamiR Therapeutics, Dr. Esau served as the Chief Scientific Officer wherein she worked to develop a microRNA-based therapy for the treatment of obesity.
Educational Profile - Dr. Esau holds a Bachelor of Science (B.S.) degree in Biology from the California Institute of Technology. In addition, she also holds a Ph.D. degree from the Massachusetts Institute of Technology.
Appointment of a new Scientific Advisor
Alongside, Dr. Pad Chivukula, who was serving as the Chief Scientific Officer and Chief Operating Officer at Arcturus, is stepping down from these positions. He would now take on the role of the Scientific Advisor to the Company.
On his new appointment, he stated that it has been a privilege to work for Arcturus Therapeutics and that he is proud of the Company's remarkable innovations and accomplishments in advancing its diverse pipeline of RNA therapeutics. He looks forward to be part of Arcturus' enduring success as the Company continues to advance its preclinical programs.
Welcoming Remarks from Arcturus' Interim President
Mark R. Herbert re-affirmed that Christine Esau brings with her a decade of experience in microRNA drug discovery, development as well as commercialization. He was positive that Dr. Esau would immediately contribute to Arcturus' progress in developing innovative RNA medicines to transform the lives of patients with severe diseases. Alongside, he also welcomed Dr. Chivukula to his new position as the Scientific Advisor to the Company.
Stock Performance Snapshot
February 14, 2018 - At Wednesday's closing bell, Arcturus Therapeutics' stock rose 4.34%, ending the trading session at $5.53.
Volume traded for the day: 15.97 thousand shares.
After yesterday's close, Arcturus Therapeutics' market cap was at $64.48 million.
The stock is part of the Financial sector, categorized under the REIT - Office industry. This sector was up 1.8% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.